(Q33422643)

26 July 2017

1 reference

title

Pantoprazole: a new proton pump inhibitor (English)

1 reference

26 July 2017

P W Jungnickel

1

1 reference

26 July 2017

publication date

1 November 2000

1 reference

26 July 2017

published in

Clinical Therapeutics

1 reference

26 July 2017

volume

22

1 reference

26 July 2017

issue

11

1 reference

26 July 2017

page(s)

1268-1293

1 reference

Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Continuing development of acid pump inhibitors: site of action of pantoprazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Effect of repeated oral administration of BY 1023/SK&F 96022--a new substituted benzimidazole derivative--on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Effects of oral pantoprazole on 24-hour intragastric acidity and plasma gastrin profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Morning and evening administration of pantoprazole: a study to compare the effect on 24-hour intragastric pH.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole--comparison of 24-hour intragastric and oesophageal pH

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Antibacterial activity of pantoprazole and omeprazole againstHelicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Drug interactions with proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pharmacokinetics of pantoprazole in patients with end-stage renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pantoprazole versus ranitidine in the treatment of duodenal ulcer: a multicenter study in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer-Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pantoprazole versus omeprazole in the treatment of acute gastric ulcers.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Bleeding peptic ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Drugs for pH control in upper gastrointestinal bleeding.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pantoprazole suppresses Helicobacter pylori without affecting cure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Multiple organ failure related to pantoprazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Lichenoid drug eruption with proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Lack of pharmacokinetic interaction of pantoprazole with diazepam in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Pantoprazole does not affect cyclosporin A blood concentration in kidney-transplant patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983025-8

7 January 2021

10.1016/S0149-2918(00)83025-8

Identifiers

DOI

1 reference

26 July 2017

1 reference